Can we overcome the predestined poor survival of diabetic patients? Perspectives from pre- and post-dialysis

Peritoneal Dialysis International

Volumn 27, Issue SUPPL. 2, 2007, Pages

  Kim, Yong Lim ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

Cardiovascular disease; Diabetes; Survival

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIOXIDANT; ATORVASTATIN; CARBONYL DERIVATIVE; DIALYSIS FLUID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICODEXTRIN; IRBESARTAN; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PRAVASTATIN; RAMIPRIL; ROSIGLITAZONE;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DIETARY INTAKE; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATIENT REFERRAL; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RISK REDUCTION; SURVIVAL RATE;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETIC NEPHROPATHIES; DIALYSIS SOLUTIONS; HUMANS; HYPERTENSION; PERITONEAL DIALYSIS; RISK FACTORS; SURVIVAL RATE;

EID: 35748965900     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. Diamond J. The double puzzle of diabetes. Nature 2003; 423:599-602.
2. USRDS. Excerpts From the United States Renal Data System 2005 Annual Data Report. Am J Kidney Dis 2006; 47(Suppl 1):S1.
3. USRDS. Excerpts from the United States Renal Data System 2001 Annual Data Report. Am J Kidney Dis 2001; 38(Suppl 3):S1.
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.
5. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44(Suppl 2):S14-21.
6. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002; 288:2579-88.
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813-20.
8. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, et al. Modification of LDL by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A 1994; 91: 9441-5.
9. Dursun E, Timur M, Dursun B, Suleymanlar G, Ozben T. Protein oxidation in type 2 diabetic patients on hemodialysis. J Diabetes Complications 2005; 19:142-6.
10. Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH. Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 2003; 46:1402-7.
11. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backtund JY, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348:2294-302.
12. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-53.
13. U.K. Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose controlwith sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53.
14. Selvin E, Coresh J, Golden SH, Boland LL, Brancati FL, Steffes MW. Glycemic control, atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes: the Atherosclerosis Risk In Communities study. Diabetes Care 2005; 28:1965-73.
15. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Milch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-9.
16. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-60.
17. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-93.
18. Wu MS, Lin CL, Chang CT, Wu CH, Huang JY, Yang CW. Improvement in clinical outcome by early nephrology referral in type II diabetics on maintenance peritoneal dialysis. Perit Dial Int 2003; 23:39-45.
19. Boner G, Cooper ME, McCarroll K, Brenner BM, de Zeeuw D, Kowey PR, et al. Adverse effects of left ventricular hypertrophy in the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study. Diabetologia 2005; 48:1980-7.
20. Wang TY, Szeto CC, Chow KM, Leung CB, Lain CW, Li PK. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 2005; 46:713-19.
21. Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, et al. Effect of pravastatin in peopte with diabetes and chronic kidney disease. J Am Soc Nephrol 2005; 16: 3748-54.
22. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-48.
23. Oomichi T, Emoto M, Tabata T, Morioka T, Tsujimoto Y, Tahara H, et al. Impact of gtycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observationat study. Diabetes Care 2006; 29:1496-500.
24. Lee HY, Choi HY, Park HC, Seo BJ, Do JY, Yun SR, et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP sotutions improves patient outcome. Nephrol Dial Transplant 2006; 21:2893-9.
25. Rossing P. Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia 2006; 49:11-19.
26. Heart Outcomes Prevention Evaluation study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mettitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-9.
27. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351:1106-18.
28. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet 2005; 366:1279-89.
29. Devaraj S, Jialal I. Alpha tocopherol supptementation decreases serum C-reactive protein and monocyte interteukin-6 levels in normal volunteers and type 2 diabetic patients. Free Radio Biol Med 2000; 29:790-2.
30. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, et al. Secondary prevention with antioxidants of cardiovascular disease in end stage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-18.
31. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107:992-5.
32. Vonesh EF, Snyder JJ, Foley RN, Collins AJ. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int 2004; 66:2389-401.
33. Locatetti F, Pozzoni P, Del Vecchio L. Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol 2004; 15(Suppl 1):S25-9.
34. Heaf JG, Lokkegaard H, Madsen M. Initial survival advantage of peritoneal dialysis relative to haemodialysis. Nephrol Dial Transplant 2002; 17:112-17.
35. Quan L, Xu Y, Luo SP, Wang L, LeBlanc D, Wang T. Negotiated care improves fluid status in diabetic peritoneal dialysis patients. Perit Dial Int 2006; 26:95-100.
36. Zeier M, Schwenger V, Deppisch R, Haug U, Weiget K, Bahner U, et al. glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003; 63:298-305.
37. Justo P, Sanz AB, Egido J, Ortiz A. 3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 2005; 54:2424-9.
38. Singh R, Barden A, Mari T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44:129-46.
39. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane. Kidney Int 2004; 66:408-18.
40. Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a doubte-blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338-44.
41. Konings CJ, Kooman JP, Schonck M, Gladziwa U, Wirtz J, van den Wall Bake AW, et al. Effect of icodextrin on volume status, brood pressure and echocardiographic parameters: a randomized study. Kidney Int 2003; 63:1556-63.
42. Furuya R, Odamaki M, Kumagai H, Hishida A. Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant 2006; 21:494-8.
43. Marshall J, Jennings P, Scott A, Fluck RJ, McIntyre CW. Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 2003; 64:1480-6.